Return to homepagePandemic Pact

Microfluidic-based direct identification of virus-neutralizing antibodies from comprehensive B-cell repertoires of elite controllers of infection (##DIVA#) for a rapid anti-pandemic response

Grant number: 46963.1 IP-LS

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $418,896.8

  • Funder

    Innosuisse

  • Principal Investigator

    Professor Doktor Sven Panke

  • Research Location

    Switzerland

  • Lead Research Institution

    Swiss Innovation Agency

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Innovation

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The innovative microfluidic screening platform #DIVA will allow direct discovery of neutralizing antibodies against viral infections and thus shorten the drug development process. It will be benchmarked with the current pandemic SARS-CoV-2 and applied to the discovery of CMV-neutralizing antibodies.